Heuron, a medical AI company specializing in brain neurological disorders, has achieved consecutive regulatory approvals in Malaysia and Singapore, strengthening its commercial presence across Southeast Asia. The clearances cover an AI stroke diagnosis suite and an Alzheimer's disease analysis tool, reflecting the company's expanding product pipeline across acute and neurodegenerative care. These milestones provide a foundation for Heuron's broader Asian market strategy and its efforts to accelerate overseas sales growth.
Malaysian Regulatory Clearance for Stroke AI
Heuron announced that its stroke diagnosis support software, Heuron StroCare Suite, has received medical device approval from Malaysia's Medical Device Authority. The solution uses AI to automatically analyze brain CT images and promptly identify stroke-related abnormalities, supporting clinicians in both diagnosis and treatment decisions. The product has also received approvals in Taiwan and Japan, reinforcing its regulatory footprint in Asia.
Strengthening a Domestic and Regional Regulatory Base
Before pursuing Southeast Asian expansion, Heuron built its technical foundation through three domestic approvals from South Korea's Ministry of Food and Drug Safety. These Grade 3 clearances cover non-contrast CT-based stroke solutions including Heuron ELVO, Heuron ICH, and Heuron ASPECTS, underscoring the company's strength in stroke imaging. The company has converted this regulatory experience into broader acceptance across major Asian healthcare markets and related medical device evaluation frameworks.
Singapore Approval Expands Neurodegenerative Disease Portfolio
In Singapore, Heuron received Health Sciences Authority approval for Heuron AD, an AI tool that analyzes brain MRI scans and quantifies atrophy in key brain regions. It assists the evaluation of degenerative brain conditions, including Alzheimer's disease, by providing objective imaging-based measurements that can support clinical decision-making. Together with the previously approved Heuron IPD for Parkinson's disease, this clearance expands the company's neurodegenerative disease AI portfolio in Singapore.
Clinical Relevance in Time-Sensitive Neurological Care
Stroke and neurodegenerative diseases require timely and accurate imaging assessment, especially in markets where specialist radiologists may be limited. AI-based tools such as Heuron StroCare Suite and Heuron AD can help reduce assessment time and support more consistent clinical decisions. These capabilities are particularly relevant for hospitals seeking to strengthen neurological care pathways and improve patient outcomes.
Heuron Global Joint Venture Supports Regional Expansion
To accelerate systematic entry into Asian markets, Heuron established a joint venture named Heuron Global in Bangkok, Thailand on January 12, 2026. The entity is actively driving business across Singapore, Vietnam, Indonesia, Malaysia, and India, covering some of the region's largest healthcare opportunities. It provides a regional platform for connecting regulatory approvals with local partnerships and clinical adoption efforts in diverse medical settings across Asia.
Leadership Outlines Commercial Strategy
Chief Executive Officer Shin Dong-hoon described the Malaysian and Singaporean approvals as an important foundation for expanding Heuron's stroke and neurodegenerative disease AI products into major Asian markets. He said the company will pursue country-specific clearances and local partnerships through Heuron Global to increase adoption in real clinical settings. The strategy is intended to convert Asian market activities into substantial overseas revenue growth while strengthening long-term regional partnerships.
These regulatory milestones indicate that Heuron is moving beyond domestic success to build a broad commercial footprint in Asia's dynamic medical technology landscape. The approvals in Malaysia and Singapore validate the clinical applicability of its AI tools across stroke and neurodegeneration, two high-priority areas of healthcare demand. With a dedicated joint venture and expanding regional clearances, Heuron appears positioned to pursue sustained international growth while addressing unmet diagnostic needs.